N
Nagaraja
About Nagaraja
Nagaraja has 8 years in corporate governance. Holds Director and Additional Director roles. Currently with 3 companies, including Orgenesis India Biotech Private Limited and Neulabs India Healthcare Private Limited. Formerly with 1 company, such as Pro Diagnostics Healthcare Llp. Engaged in Technology, Healthcare and more. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Orgenesis India Biotech Private Limited
U86900KA2025PTC205201
|
Director | 08 Jul 2025 | 2025 | Active |
Neulabs India Healthcare Private Limited
U85300KA2021PTC149451
|
Additional Director | 04 Mar 2024 | 2021 | Active |
Adrithi Holdings Consultancy Private Limited
U70200KA2023PTC177543
|
Director | 20 Aug 2023 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Pro Diagnostics Healthcare Llp
AAL-4465
|
Designated Partner | 19 Dec 2017 | 2017 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Nagaraja
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nagaraja
Nagaraja has 8 years in corporate governance. Holds Director and Additional Director roles. Currently with 3 companies, including Orgenesis India Biotech Private Limited and Neulabs India Healthcare Private Limited. Formerly with 1 company, such as Pro Diagnostics Healthcare Llp. Engaged in Technology, Healthcare and more. Contributes to corporate operations.
Nagaraja is associated with 3 companies as Director and Additional Director.
Nagaraja has expertise in Technology, Healthcare and other sectors.
Nagaraja has 8 years in corporate governance.